- Home
- LPLA vs IMTXW Comparison
LPLA vs IMTXW Comparison
Compare LPLA & IMTXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPLA
- IMTXW
- Stock Information
- Founded
- LPLA 1989
- IMTXW N/A
- Country
- LPLA United States
- IMTXW Germany
- Employees
- LPLA N/A
- IMTXW 343
- Industry
- LPLA Investment Bankers/Brokers/Service
- IMTXW Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LPLA Finance
- IMTXW Health Care
- Exchange
- LPLA Nasdaq
- IMTXW Nasdaq
- Market Cap
- LPLA 15.8B
- IMTXW N/A
- IPO Year
- LPLA 2010
- IMTXW N/A
- Fundamental
- Price
- LPLA $256.08
- IMTXW $1.18
- Analyst Decision
- LPLA Buy
- IMTXW
- Analyst Count
- LPLA 15
- IMTXW 0
- Target Price
- LPLA $276.86
- IMTXW N/A
- AVG Volume (30 Days)
- LPLA 858.9K
- IMTXW N/A
- Earning Date
- LPLA 10-30-2024
- IMTXW N/A
- Dividend Yield
- LPLA 0.47%
- IMTXW N/A
- EPS Growth
- LPLA N/A
- IMTXW N/A
- EPS
- LPLA 12.80
- IMTXW N/A
- Revenue
- LPLA $10,930,574,000.00
- IMTXW N/A
- Revenue This Year
- LPLA $20.61
- IMTXW N/A
- Revenue Next Year
- LPLA $16.64
- IMTXW N/A
- P/E Ratio
- LPLA $20.01
- IMTXW N/A
- Revenue Growth
- LPLA 16.49
- IMTXW N/A
- 52 Week Low
- LPLA $187.19
- IMTXW N/A
- 52 Week High
- LPLA $289.88
- IMTXW N/A
- Technical
- Relative Strength Index (RSI)
- LPLA 68.14
- IMTXW N/A
- Support Level
- LPLA $254.31
- IMTXW N/A
- Resistance Level
- LPLA $263.45
- IMTXW N/A
- Average True Range (ATR)
- LPLA 5.52
- IMTXW 0.00
- MACD
- LPLA 1.09
- IMTXW 0.00
- Stochastic Oscillator
- LPLA 78.48
- IMTXW 0.00
About LPLA LPL Financial Holdings Inc.
LPL Financial Holdings is an independent broker/dealer that provides a platform of proprietary technology, brokerage, and investment advisory services to financial advisors and institutions. As of the end of 2023, the company had over 20,000 advisors on its platform managing over $1.3 trillion of client assets.
About IMTXW Immatics N.V.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.